What does Deconib do?

Deconib is registered with the CBE as active in: Activiteiten van holdings. Public Limited, started on 21 December 1983, 1 establishment.

What is the address of Deconib?

The registered office of Deconib is located at Aalterbaan 119, 9990 Maldegem.

Is Deconib still active?

Yes. According to the CBE (30 October 2026) Deconib is active, legal situation “Normale toestand”, started on 21 December 1983.

Is Deconib registered on Peppol?

Yes, Deconib is registered on the Peppol network with ID 0208:0425919575.

What is the enterprise number of Deconib?

The enterprise number of Deconib is BE0425919575.

When was Deconib founded?

Deconib was founded on 21 December 1983.

Who are the directors of Deconib?

According to the 2025 annual accounts, the directors of Deconib are: DENCON BV, FRONT ROW MANAGEMENT BV.

Is Deconib a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 21 December 1983; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did Deconib make in 2025?

Deconib posted a profit after taxes of € 279,063 in financial year 2025.

What is the revenue of Deconib?

As a small company, Deconib is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 1,210,334.

How much does an employee at Deconib earn?

The average wage cost per full-time employee at Deconib was € 148,800 in 2025: staff costs of € 148,807 for 1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Deconib have?

According to the 2025 annual accounts, Deconib has 1 full-time equivalents (FTE).

Deconib (Public Limited) - Maldegem - BE0425919575

Dossier Deconib, printed on 30 October 2026 from databakkes.be/en/0425919575/deconib. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 11 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Deconib from Maldegem, company number BE0425919575, closed financial year 2025 with a result of € 279,063 after tax. For that financial year Deconib recorded a gross margin of € 1.2 million and equity of € 3.3 million. Compared with financial year 2024, the result moved from € 202,738 to € 279,063. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 29, 2026.

What it is worth Growing

€ 3.3 million

▲ 9% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 279,063

▲ 38% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 114,234

▼ 14% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1.7 million.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 148,807

▼ 29% vs 2024

€ 148,800 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 235,865

▲ 154% vs 2024

Of which on lease € 235,865.

Debts at end 2025

Bank debt ≈ 8 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 2.2 million

▲ 13% vs 2024

€ 256,797 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.

Owed to suppliers

€ 165,178

▲ 89% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 37,802

▼ 32% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 1,008,623 Gross margin 2022: € 1,008,623 First fiscal year in the series	€ 1,038,777 Gross margin 2023: € 1,038,777 ▲ 3% vs 2022 (€ 1,008,623) Favourable step	€ 1,150,667 Gross margin 2024: € 1,150,667 ▲ 11% vs 2023 (€ 1,038,777) Favourable step	€ 1,210,334 Gross margin 2025: € 1,210,334 ▲ 5% vs 2024 (€ 1,150,667) Favourable step	▲ 5%
Profit after taxes	€ 31,491 Profit after taxes 2022: € 31,491 First fiscal year in the series	€ 171,100 Profit after taxes 2023: € 171,100 ▲ € 139,609 vs 2022 (€ 31,491) Favourable step	€ 202,738 Profit after taxes 2024: € 202,738 ▲ 18% vs 2023 (€ 171,100) Favourable step	€ 279,063 Profit after taxes 2025: € 279,063 ▲ 38% vs 2024 (€ 202,738) Favourable step	▲ 38%
Equity	€ 3,497,545 Equity 2022: € 3,497,545 First fiscal year in the series	€ 2,804,645 Equity 2023: € 2,804,645 ▼ 20% vs 2022 (€ 3,497,545) Unfavourable step	€ 3,007,382 Equity 2024: € 3,007,382 ▲ 7% vs 2023 (€ 2,804,645) Favourable step	€ 3,286,445 Equity 2025: € 3,286,445 ▲ 9% vs 2024 (€ 3,007,382) Favourable step	▲ 9%
Total debts	€ 4,746,070 Total debts 2022: € 4,746,070 First fiscal year in the series	€ 5,228,745 Total debts 2023: € 5,228,745 ▲ 10% vs 2022 (€ 4,746,070) Unfavourable step	€ 5,835,987 Total debts 2024: € 5,835,987 ▲ 12% vs 2023 (€ 5,228,745) Unfavourable step	€ 6,189,468 Total debts 2025: € 6,189,468 ▲ 6% vs 2024 (€ 5,835,987) Unfavourable step	▲ 6%
Cash	€ 128,982 Cash 2022: € 128,982 First fiscal year in the series	€ 80,810 Cash 2023: € 80,810 ▼ 37% vs 2022 (€ 128,982) Unfavourable step	€ 133,144 Cash 2024: € 133,144 ▲ 65% vs 2023 (€ 80,810) Favourable step	€ 114,234 Cash 2025: € 114,234 ▼ 14% vs 2024 (€ 133,144) Unfavourable step	▼ 14%
Land & buildings	€ 1,202,852 Land & buildings 2022: € 1,202,852 First fiscal year in the series	€ 1,255,526 Land & buildings 2023: € 1,255,526 ▲ 4% vs 2022 (€ 1,202,852) Unchanged	€ 2,294,303 Land & buildings 2024: € 2,294,303 ▲ 83% vs 2023 (€ 1,255,526) Unchanged	€ 2,868,044 Land & buildings 2025: € 2,868,044 ▲ 25% vs 2024 (€ 2,294,303) Unchanged	▲ 25%
Retained profit	€ 1,923,421 Retained profit 2022: € 1,923,421 First fiscal year in the series	€ 1,230,521 Retained profit 2023: € 1,230,521 ▼ 36% vs 2022 (€ 1,923,421) Unfavourable step	€ 1,433,258 Retained profit 2024: € 1,433,258 ▲ 16% vs 2023 (€ 1,230,521) Favourable step	€ 1,712,321 Retained profit 2025: € 1,712,321 ▲ 19% vs 2024 (€ 1,433,258) Favourable step	▲ 19%
Dividend	€ 864,000 Dividend 2022: € 864,000 First fiscal year in the series	€ 864,000 Dividend 2023: € 864,000 Unchanged (€ 864,000) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 864,000) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 1,733,892 Bank debt 2022: € 1,733,892 First fiscal year in the series	€ 1,354,787 Bank debt 2023: € 1,354,787 ▼ 22% vs 2022 (€ 1,733,892) Favourable step	€ 1,945,319 Bank debt 2024: € 1,945,319 ▲ 44% vs 2023 (€ 1,354,787) Unfavourable step	€ 2,199,064 Bank debt 2025: € 2,199,064 ▲ 13% vs 2024 (€ 1,945,319) Unfavourable step	▲ 13%
Balance sheet total	€ 8,560,060 Balance sheet total 2022: € 8,560,060 First fiscal year in the series	€ 8,271,023 Balance sheet total 2023: € 8,271,023 ▼ 3% vs 2022 (€ 8,560,060) Unchanged	€ 9,063,258 Balance sheet total 2024: € 9,063,258 ▲ 10% vs 2023 (€ 8,271,023) Unchanged	€ 9,653,750 Balance sheet total 2025: € 9,653,750 ▲ 7% vs 2024 (€ 9,063,258) Unchanged	▲ 7%
Employees (FTE)	1 Employees (FTE) 2022: 1 First fiscal year in the series	1 Employees (FTE) 2023: 1 Unchanged (1) Unchanged	1 Employees (FTE) 2024: 1 Unchanged (1) Unchanged	1 Employees (FTE) 2025: 1 Unchanged (1) Unchanged

Key figures of Deconib, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Deconib?

What happened at Deconib in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 29, 2026 New annual accounts for financial year 2025: profit of € 279,063 (▲ 38% vs 2024). filed late Source: NBB ↗
2021 DENCON BV became a director. NBB
2021 FRONT ROW MANAGEMENT BV became a director. NBB
Dec 21, 1983 New establishment in Maldegem. KBO
Dec 21, 1983 Start of the company according to the CBE. KBO

In short

From € 31,491 profit in 2022 to € 279,063 profit in 2025.

Paid € 474,424 in corporate taxes since 2022.

Best year ever: 2025, with € 279,063 profit.

On average € 1.2 million of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

FRONT ROW MANAGEMENT 50%

DENCON 50%

The stake of FRONT ROW MANAGEMENT, DENCON comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Deconib

VAN LANDSCHOOT 100%

DECOMAT 100%

Behind Deconib are DENCON BV and FRONT ROW MANAGEMENT BV. The shares are held by FRONT ROW MANAGEMENT (50%) and DENCON (50%). It owns 100% of VAN LANDSCHOOT and 100% of DECOMAT itself.

Directors

According to the 2025 annual accounts

DENCON BV

Managing director · represented by Dennis De Coninck

Also active at: Matrassenfabriek Van Landschoot, NEW-HERMAT, DECOMAT

since 2021

FRONT ROW MANAGEMENT BV

Managing director · represented by Rowany De Coninck

Also active at: Matrassenfabriek Van Landschoot, NEW-HERMAT, DECOMAT

since 2021

Shareholders

FRONT ROW MANAGEMENT

50%

DENCON

50%

Participations

VAN LANDSCHOOT

100%

DECOMAT

100%

Establishments

Establishment units

Physical locations of this company

Registered office

Aalterbaan 119

9990 Maldegem

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.

All companies at this address →

Matrassenfabriek Van Landschoot same network

€ 19.3 million revenue · 2025

DECOMAT same network

€ 270,554 gross margin · 2025

VIJFHAND

GROEP VAN LANDSCHOOT

FRONT ROW MANAGEMENT same network

€ 97,577 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0425.919.575

VAT number

BE 0425.919.575

Registered office

Aalterbaan 119, 9990 Maldegem

Names & denominations

Deconib

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

21 December 1983

Peppol

Active · Active since 13 Oct 2025

Activities · NACE

Activiteiten van holdings

Marktonderzoekbureaus

Holdings

Markt- en opinieonderzoek

Verhuur en lease van machines en installaties voor de bouwnijverheid en de weg- en waterbouw

View on CBE Public ↗ Annual accounts (NBB) ↗

Deconib

Warning lights

Financials

What happened to Deconib?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions